National Institute on Drug Abuse; Notice of Closed Meeting, 67363-67364 [2020-23370]

Download as PDF Federal Register / Vol. 85, No. 205 / Thursday, October 22, 2020 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: Development of a Topical Ointment Containing Immunostimulatory CpG Oligodeoxynucleotides (ODN) for Dermatological Wound Healing AGENCY: National Institutes of Health, HHS ACTION: Notice. The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Six Therapeutics Technologies Holdings Group. (‘‘Six Therapeutics’’) located in New Jersey. DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before November 6, 2020 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: *** Rose. M. Freel, Ph.D., Senior Licensing and Patenting Manager, NCI Technology Transfer Center at (301) 624–8775 or Email: rose.freel@nih.gov. SUPPLEMENTARY INFORMATION: SUMMARY: Intellectual Property United States Provisional Patent Application No. 61/639,688, filed April 27, 2012 and entitled ‘‘Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing’’ [HHS Reference No. E–294–2011/0–US– 01]; PCT Patent Application PCT/US2013/ 034639, filed March 29, 2013 and entitled ‘‘Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing’’ [HHS Reference No. E–294–2011/0–PCT–02]; Australian Patent No. 2013252785, filed March 29, 2013, issued August 24, 2017, and entitled ‘‘Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing’’ [HHS Reference No. E–294–2011/0–AU– 03]; Canadian Patent Application No. 2871490, filed March 29, 2013, and entitled ‘‘Use of CPG oligonucleotides VerDate Sep<11>2014 17:35 Oct 21, 2020 Jkt 253001 co-formulated with an antibiotic to accelerate wound healing’’ [HHS Reference No. E–294–2011/0–CA–04]; U.S. Patent No. 10,076,535, filed October 24, 2014, issued September 18, 2018, and entitled ‘‘Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing’’ [HHS Reference No. E–294–2011/0–US– 05]; and U.S. Patent No. 8,466,116, filed September 5, 2008, issued June 18, 2013, and entitled ‘‘Use Of CpG Oligodeoxynucleotides To Induce Epithelial Cell Growth’’ [HHS Reference No. E–328–2001/1–US–01]. The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to: ‘‘Topical ointment containing K-type CpG oligodeoxynucleotides that activate Toll-like receptor 9 to induce angiogenesis and epithelial cell growth, alone or in combination with other agents, for dermatological wound healing.’’ This technology discloses the use of CpG oligodeoxynucleotides (ODNs) to accelerate wound healing. The E–294– 2011/0, technology relates to an antibiotic composition containing the toll-like receptor-7 (TLR7) ligand (imidazoquinoline) and an immunostimulatory K ODN. There is evidence that this formulation may produce more rapid wound healing versus standard antibiotic formulations. Because standard antibiotics eliminate bacteria at a wound site, they also eliminate the molecular signals present in bacterial DNA that stimulate the immune system’s wound healing processes. The ODN and imidazoquinoline act as artificial immune stimulants that mimic the bacterial signals to improve healing rates. The E–328–2001/1 technology relates to a method of inducing epithelial cell growth by administration of immunostimulatory ODNs. The stimulation of epithelial cell growth also promotes wound healing. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 67363 In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. Dated: October 15, 2020. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2020–23385 Filed 10–21–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Reducing Stigma Related to Drug Use in Human Service Settings (R34, R21). Date: December 9, 2020. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Preethy Nayar, Ph.D., M.B.B.S., M.S., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 3WFN, 9th Floor, MSC 6021, 301 North Stonestreet Avenue, Bethesda, MD 20892, 301–443–4577, nayarp2@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist E:\FR\FM\22OCN1.SGM 22OCN1 67364 Federal Register / Vol. 85, No. 205 / Thursday, October 22, 2020 / Notices Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: October 16, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–23370 Filed 10–21–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY U.S. Customs and Border Protection [1651–0030] Agency Information Collection Activities: Declaration of Unaccompanied Articles U.S. Customs and Border Protection (CBP), Department of Homeland Security. ACTION: 30-Day notice and request for comments; extension of an existing collection of information. AGENCY: The Department of Homeland Security, U.S. Customs and Border Protection will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the Federal Register to obtain comments from the public and affected agencies. Comments are encouraged and must be submitted (no later than November 23, 2020) to be assured of consideration. ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. FOR FURTHER INFORMATION CONTACT: Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229–1177, Telephone number 202–325–0056 or via email CBP_PRA@cbp.dhs.gov. Please note that the contact information provided here is solely for questions regarding this notice. Individuals SUMMARY: VerDate Sep<11>2014 18:20 Oct 21, 2020 Jkt 253001 seeking information about other CBP programs should contact the CBP National Customer Service Center at 877–227–5511, (TTY) 1–800–877–8339, or CBP website at https://www.cbp .gov/. SUPPLEMENTARY INFORMATION: CBP invites the general public and other Federal agencies to comment on the proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.). This proposed information collection was previously published in the Federal Register (Volume 85 FR Page 50831) on August 18, 2020, allowing for a 60-day comment period. This notice allows for an additional 30 days for public comments. This process is conducted in accordance with 5 CFR 1320.8. Written comments and suggestions from the public and affected agencies should address one or more of the following four points: (1) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) suggestions to enhance the quality, utility, and clarity of the information to be collected; and (4) suggestions to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. The comments that are submitted will be summarized and included in the request for approval. All comments will become a matter of public record. Title: Declaration of Unaccompanied Articles. OMB Number: 1651–0030. Form Number: CBP Form 255. Current Actions: This submission is being made to extend the expiration date of this information collection with no change to the burden hours or the information being collected. Type of Review: Extension (without change). Affected Public: Individuals. Abstract: CBP Form 255, Declaration of Unaccompanied Articles, is completed by travelers arriving in the United States with a parcel or container which is to be sent from an insular possession at a later date. It is the only means whereby the CBP officer, when the person arrives, can apply the PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 exemptions or 5 percent flat rate of duty to all of the traveler’s purchases. CBP Form 255 is authorized by 19 U.S.C. 1202 (Chapter 98, Subchapters IV and XVI) and provided for by 19 CFR 145.12, 145.43, 148.110, 148.113, 148.114, 148.115 and 148.116. A sample of this form can be viewed at https:// www.cbp.gov/newsroom/publications/ forms?title=255&=Apply#. Type of Collection: CBP Form 255. Estimated Number of Respondents: 7,500. Estimated Number of Annual Responses per Respondent: 2. Estimated Number of Total Annual Responses: 15,000. Estimated Time per Response: 5 minutes. Estimated Total Annual Burden Hours: 1,250. Dated: October 19, 2020. Seth D. Renkema, Branch Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection. [FR Doc. 2020–23438 Filed 10–21–20; 8:45 am] BILLING CODE 9111–14–P DEPARTMENT OF HOMELAND SECURITY U.S. Citizenship and Immigration Services [OMB Control Number 1615–0049] Agency Information Collection Activities; Extension, Without Change, of a Currently Approved Collection: Request for Verification of Naturalization U.S. Citizenship and Immigration Services, Department of Homeland Security. ACTION: 30-Day notice. AGENCY: The Department of Homeland Security (DHS), U.S. Citizenship and Immigration Services (USCIS) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995. The purpose of this notice is to allow an additional 30 days for public comments. DATES: Comments are encouraged and will be accepted until November 23, 2020. SUMMARY: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, must be submitted via the Federal eRulemaking Portal website at https:// ADDRESSES: E:\FR\FM\22OCN1.SGM 22OCN1

Agencies

[Federal Register Volume 85, Number 205 (Thursday, October 22, 2020)]
[Notices]
[Pages 67363-67364]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-23370]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Reducing Stigma Related to Drug Use in Human Service 
Settings (R34, R21).
    Date: December 9, 2020.
    Time: 10:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Preethy Nayar, Ph.D., M.B.B.S., M.S., Scientific 
Review Officer, Scientific Review Branch, National Institute on Drug 
Abuse, NIH, 3WFN, 9th Floor, MSC 6021, 301 North Stonestreet Avenue, 
Bethesda, MD 20892, 301-443-4577, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist

[[Page 67364]]

Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: October 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-23370 Filed 10-21-20; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.